Several categories of peptides can promote muscle growth, each working through a different biological mechanism. The most widely discussed include growth hormone-releasing peptides (like GHRP-2, GHRP-6, and ipamorelin), growth hormone-releasing hormone analogs (like tesamorelin and CJC-1295), IGF-1 variants, recovery peptides like BPC-157, and myostatin inhibitors like follistatin. Before you explore any of these, it’s worth understanding that most lack robust human clinical data, and several have recently been restricted by the FDA due to safety concerns.
Growth Hormone Releasing Peptides
Growth hormone releasing peptides, commonly known as GHRPs, work by signaling your pituitary gland to produce more growth hormone. Your body then converts that growth hormone into IGF-1, primarily in the liver, and IGF-1 is the molecule that actually drives muscle protein synthesis. The key peptides in this category are GHRP-2, GHRP-6, and ipamorelin.
What makes GHRPs appealing is that they stimulate your body’s own growth hormone production rather than injecting synthetic growth hormone directly. They also preserve the normal feedback loops that prevent growth hormone levels from climbing dangerously high. When combined with GHRH peptides (covered below), GHRPs produce a synergistic effect, meaning the two together release significantly more growth hormone than either one alone.
The trade-off is metabolic side effects. GHRP-6 in particular has been linked to decreased insulin sensitivity and increased blood glucose. GHRP-2 has been associated with reports of increased insulin requirements and, in critically ill patients, serious adverse events including death, though direct causality wasn’t established. More broadly, artificially elevating growth hormone over time can lead to fluid retention, joint pain, carpal tunnel syndrome, numbness and tingling, and in extreme cases, enlargement of facial features, hands, and feet.
GHRH Analogs: Tesamorelin and CJC-1295
While GHRPs act on one receptor, GHRH analogs act on a completely different one. They mimic the hormone your hypothalamus naturally releases to trigger growth hormone production. The two most commonly referenced are tesamorelin and CJC-1295.
Tesamorelin is the only peptide in this group with meaningful clinical trial data for muscle effects. In a 26-week study of adults with HIV-related body composition changes, tesamorelin significantly increased both muscle density and muscle area across four core muscle groups compared to placebo. The largest improvement was in the rectus abdominis, where muscle density increased by 3.5 Hounsfield units (a measure of tissue quality on imaging). Lean muscle area improvements were nearly double the gains seen in total muscle area, meaning the peptide reduced fat within the muscle while also building new tissue. Tesamorelin is FDA-approved, though only for a specific indication related to HIV-associated excess abdominal fat.
CJC-1295 is a modified GHRH analog with a longer half-life, often paired with ipamorelin in anti-aging and performance clinics. Its muscle-building evidence is largely anecdotal and based on the assumption that sustained growth hormone elevation translates to meaningful hypertrophy.
IGF-1 Variants
IGF-1 is the downstream hormone that does much of the actual muscle-building work after growth hormone is released. Rather than raising growth hormone and waiting for IGF-1 to follow, some peptides deliver IGF-1 or modified versions of it directly. The two most discussed variants are IGF-1 LR3 and IGF-1 DES.
IGF-1 LR3 has a longer active life in the body because it doesn’t bind as readily to the proteins that normally neutralize IGF-1. This gives it more time to reach muscle tissue. IGF-1 DES is a truncated version that acts quickly and locally, often discussed in the context of site-specific injections near a target muscle. Natural IGF-1 has a very short half-life, and its binding proteins keep it localized near the tissue that produced it. This is actually a feature: skeletal muscle makes its own IGF-1, and that local supply appears sufficient to sustain muscle growth without needing high levels circulating through the bloodstream.
Research has shown that a precursor form of IGF-1 (pro-IGF-1) causes roughly 30% more receptor activation than the mature form at equivalent doses, suggesting the body’s natural packaging of IGF-1 may be more potent than the isolated molecule. The practical challenge with all IGF-1 variants is getting enough of the peptide to muscle tissue through injection while avoiding systemic risks, which include low blood sugar and potentially accelerated growth of abnormal cells.
BPC-157 for Muscle Recovery
BPC-157 doesn’t build muscle in the traditional anabolic sense. Instead, it accelerates repair, which indirectly supports muscle growth by shortening recovery time between training sessions and improving healing after injury. It’s derived from a protective protein found in human gastric juice.
In animal studies, BPC-157 enhances muscle fiber regeneration and functional recovery after injury. It does this through several pathways at once: it promotes new blood vessel formation by boosting signaling that increases blood flow to damaged tissue, it stimulates the cells responsible for producing collagen and connective tissue, and it helps rebuild the junctions where muscles attach to tendons. BPC-157 also increases the expression of growth hormone receptors on repair cells, which amplifies the body’s existing anabolic signals at the injury site. These effects kick in within minutes of administration and trigger gene expression cascades that continue independently afterward.
The animal data is genuinely impressive for musculoskeletal healing, with reduced scarring and faster return of contractile function. But no controlled human trials have confirmed these effects, and the FDA has flagged BPC-157 as lacking sufficient safety data for human use.
Follistatin and Myostatin Inhibition
Myostatin is a protein your body produces specifically to limit muscle growth. Block it, and muscles grow larger. Follistatin is a natural myostatin inhibitor, and the synthetic version follistatin-344 has shown the strongest effects in preclinical research.
In a landmark mouse study, a single gene-based administration of follistatin-344 produced increased muscle mass and strength that persisted for over two years. When delivered to older animals (at 210 days of age, roughly equivalent to middle-aged), muscle strength increased within 60 days and remained elevated for the entire 560-day observation period. The strength gains were dose-dependent, with higher doses producing greater improvements. Among several myostatin-blocking approaches tested, follistatin-344 produced the greatest effects on both muscle size and function with no adverse effects on heart tissue or reproductive capacity.
This remains entirely preclinical. No human trials of follistatin-344 peptide for muscle building have been published. The concept is sound, and researchers have called it a promising strategy worth pursuing in clinical trials for muscle diseases, but it has not crossed that threshold yet.
Regulatory Status in the U.S.
The FDA has placed several of the most popular muscle-building peptides on a list of substances that may present significant safety risks when used in compounded medications. This effectively removes them from legal compounding pharmacies, which had been the primary source for people using these peptides.
BPC-157 is on the list because the FDA says it lacks sufficient safety data for the routes people typically use it (injection). Ipamorelin is flagged for immunogenicity risks and because a published study identified serious adverse events, including death, when it was given intravenously. GHRP-2 and GHRP-6 are both listed, with GHRP-2 linked to serious adverse event reports and GHRP-6 to concerns about cortisol disruption and blood sugar elevation.
Tesamorelin is the notable exception. It’s an FDA-approved pharmaceutical available by prescription, though only for its approved indication. IGF-1 variants and follistatin peptides exist in a gray area, largely available through research chemical suppliers rather than pharmacies, with no regulatory approval for human use.
What Actually Works vs. What’s Theoretical
If you line up all the peptides discussed in fitness communities, the evidence breaks into clear tiers. Tesamorelin has human clinical trial data showing measurable improvements in muscle density and area over 26 weeks. It’s the only peptide in this space with that level of proof. GHRPs and GHRH analogs have solid mechanistic evidence showing they raise growth hormone, but the leap from “higher growth hormone” to “meaningfully more muscle” in otherwise healthy adults who are already training is not well documented in controlled trials.
BPC-157 has compelling animal data for tissue repair but zero controlled human evidence. Follistatin has extraordinary preclinical results in mice but hasn’t been tested in humans for muscle growth. IGF-1 variants face fundamental delivery challenges that limit how much peptide actually reaches your muscles through injection.
For someone training consistently and eating enough protein, the marginal benefit of most peptides over those fundamentals is unclear. The people most likely to see meaningful effects are those with clinical deficiencies in growth hormone, those recovering from injury, or those with muscle-wasting conditions, which is exactly the population where the limited human data exists.